CREATININE SULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C4H7N3O.H2O4S
Molecular Weight	211.196
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.CN1CC(=O)N=C1N

InChI

InChIKey=MEVXSUZBFYZPHZ-UHFFFAOYSA-N

InChI=1S/C4H7N3O.H2O4S/c1-7-2-3(8)6-4(7)5;1-5(2,3)4/h2H2,1H3,(H2,5,6,8);(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H7N3O
Molecular Weight	113.1179
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.webmd.com/a-to-z-guides/creatinine-and-creatinine-clearance-blood-tests | https://www.ncbi.nlm.nih.gov/pubmed/3532908

Creatinine is a product of metabolism of creatine phosphate, a molecule that serves as a rapidly mobilizable reserve of a brain and skeletal muscle. Creatinine is excreted by kidneys with little or no reabsorption. Serum creatinine is the most commonly used indicator of renal function.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Renal failure 9 Sources: https://www.webmd.com/a-to-z-guides/creatinine-and-creatinine-clearance-blood-tests	Diagnostic		Natural Metabolite	Unknown Approved Use Unknown
Sunburn 84 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac2cc22b-725e-487b-bd02-b022f974f972	Inactive ingredient		Approved 8583	AGELOC TRANSFORMATION Approved Use Helps to prevent sunburn. Launch Date 2013

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
activator 150 substrate 1946			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B3 961 OCT1 620 OCT2 779 OATP1B1 1079 OCTN2 71	MATE1 182 OCTN2 59 MATE2-K 33 P-gp 2052 OCT2 434 OAT2 125 OAT3 391 OCTN1 55 OCT3 92 OAT1 395 OAT4 93 OCT1 393

Drug as perpetrator

Target	Modality	Activity
OCT1 656	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1NTY3In19	no [Inhibition 100 uM]
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/588#section=BioAssay-Results Page: 10.0	no
OCT2 782	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1NTY3In19	no
OCTN2 71	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjkzIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1NTY3In19	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1NTY3In19	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDY1NTY3In19	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/588#section=BioAssay-Results Page: 11.0	no
OAT1 395	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OAT3 391	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OAT4 93	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OCTN1 55	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OCTN2 59	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	no
OCT3 92	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24646860/	yes [Km 1320 uM]
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27872146/ \| https://pubmed.ncbi.nlm.nih.gov/24646860/	yes [Km 1860 uM]
OAT2 125	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27872146/ \| https://pubmed.ncbi.nlm.nih.gov/24646860/	yes [Km 986 uM]
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27872146/ \| https://pubmed.ncbi.nlm.nih.gov/24646860/	yes [Km >2000 uM]
MATE2-K 33	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27872146/ \| https://pubmed.ncbi.nlm.nih.gov/24646860/	yes [Km >2000 uM]
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18930752/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/588#section=BioAssay-Results Page: 148.0

PubMed

Title	Date	PubMed
Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria.	2001-02-15	11157794
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.	2001-02-01	11166775
Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study).	2001-02-01	11165964
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.	2001-02-01	11157020
Urinary F2-isoprostanes formation in kidney transplantation.	2001-02	11168317
Hyperlipidemia as a risk factor of renal allograft function impairment.	2001-02	11168315
Cyclosporine challenge test revisited: does it predict outcome after solitary pancreas transplantation?	2001-02	11168312
Diagnosis of kidney transplant obstruction using Mag3 diuretic renography.	2001-02	11168310
Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation.	2001-02	11167878
Hypoglycemic effect of the water extract of Smallantus sonchifolius (yacon) leaves in normal and diabetic rats.	2001-02	11167030
The effect of growth hormone on 24-h urinary creatinine levels in burned patients.	2001-02	11164664
Angiotensin converting enzyme inhibitor induced hyperkalaemic paralysis.	2001-02	11161080
Prospective study of hepatic, renal, and haematological surveillance in hazardous materials firefighters.	2001-02	11160986
Predictors of DMSA chelatable lead, tibial lead, and blood lead in 802 Korean lead workers.	2001-02	11160984
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.	2001-02	11158725
Brain proton magnetic resonance spectroscopy and imaging in children exposed to cocaine in utero.	2001-02	11158451
Human SA gene Pst1 polymorphism and chronic renal failure: results of the family-based study.	2001-02	11158418
Laparoscopic or open surgery for living donor nephrectomy.	2001-02	11158417
Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients.	2001-02	11158414
Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial.	2001-02	11158407
Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.	2001-02	11158405
Impaired endothelium-dependent vasodilatation in renal failure in humans.	2001-02	11158404
Variation in the progression of diabetic nephropathy according to racial origin.	2001-02	11158401
Circulating soluble adhesion molecules in ANCA-associated vasculitis.	2001-02	11158400
Paradoxical increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased activity of nitric oxide.	2001-02	11158398
Expression and characterization of recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis.	2001-02	11158397
Impact of dialysis adequacy on the mortality and morbidity of anuric Chinese patients receiving continuous ambulatory peritoneal dialysis.	2001-02	11158226
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.	2001-02	11158224
Downregulation of hepatic cytochrome P450 in chronic renal failure.	2001-02	11158222
Protein kinase C and G(i/o) proteins are involved in adenosine- and ischemic preconditioning-mediated renal protection.	2001-02	11158213
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.	2001-02	11158211
Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2.	2001-02	11158060
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.	2001-02	11158043
Reversible renal failure in paroxysmal nocturnal hemoglobinuria.	2001-02	11157403
Serum cystatin as a marker of glomerular filtration rate.	2001-02	11157392
Analysis of prognostic predictors in idiopathic membranous nephropathy.	2001-02	11157381
Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy.	2001-02	11157380
Impact of donor/recipient traits independent of rejection on long-term renal function.	2001-02	11157378
Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: a 2-year prospective study.	2001-02	11157374
Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus.	2001-01	11168340
Bone resorption is increased in young adults with thalassaemia major.	2001-01	11167780
Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis.	2001-01	11164137
In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study.	2001-01	11164120
Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme-distribution in a model of left ventricular dysfunction.	2001-01	11163728
Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits.	2001-01	11163560
Cardiovascular risk factors and the long-term outcome of lupus nephritis.	2001-01	11161132
Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients.	2001-01	11158868
Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters.	2001-01	11158867
An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats.	2001-01	11158853
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.	2001-01	11157146

Patents

Sample Use Guides

In Vivo Use Guide

Small amounts of creatinine are normally administered with food. In the study oral administration of up to 7g of creatinine does not lead to elevation of creatinine levels in the blood.

Route of Administration: Oral

In Vitro Use Guide

The blood level of creatinine is routinely measured by measurement devices. Method principles are based on a cascade of enzymatic reactions, followed by either photometric or electrochemical detection. Preferred sample types vary from whole blood to serum/plasma or both. Sample volumes range from 1 to 30 μL generally. A normal result for creatinine blood test is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:55:32 GMT 2025` Edited by `admin` on `Mon Mar 31 20:55:32 GMT 2025`
Record UNII	6LPJ42D59W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CREATININE, SULFATE (1:1)

Preferred Name

English

CREATININE SULFATE

Common Name

English

4H-IMIDAZOL-4-ONE, 2-AMINO-1,5-DIHYDRO-1-METHYL-, SULFATE (1:1)

Systematic Name

English

Creatinine sulfate [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

6LPJ42D59W